You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser or turn off compatibility mode in Internet Explorer. In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript. Although most patients with acute leukemia or MDS have a higher percentage of BM blasts than PB blasts, the relative proportion is reversed in some patients.
In multivariate analyses, these associations were independent of other relevant predictors, including cytogenetic status. These data also suggest that MDS classification schemes should take into account the percentage of blasts in PB differently from the percentage of blasts in BM. Blast percentage plays a central role in the diagnosis and classification of acute leukemias and myelodysplastic syndromes MDS.
The percentage of PB and BM blasts is not as important for the diagnosis of acute lymphoblastic leukemia ALL , because the presence of any clonal blast population is diagnostic. However, post-therapy PB blast percentage is an important prognostic index that reflects the outcome in ALL.
Although it is believed that homing molecules play a role in determining why some blasts tend to circulate in PB and some do not, the clinical relevance of circulating blasts is not well studied. Only patients treated at MD Anderson were included in the analysis. The diagnosis was based on morphologic, cytochemical, and immunophenotypic studies.
Cytogenetic analyses and molecular diagnostic studies were also performed. Disease status was classified according to the FAB system. PB smears obtained from all patients with leukemia were evaluated for the presence of blasts, irrespective of whether the automated differential leukocyte count was flagged.
Cytogenetic and molecular diagnostic studies were performed on most of the patients. The association between the clinical characteristics of the patients and the relative percentage of blasts in BM and PB was studied.
In each case, performance status was classified as 0 or 1 vs 2, 3, or 4. Antecedent hematologic disease AHD classified as positive or negative. Similarly, cytogenetic status in ALL patients was classified as favorable hyperdiploidy , unfavorable t 8,14 or t 9;22 , or intermediate others groups.
Spearman's rank correlation coefficient was used to assess correlations between variables. The Wilcoxon rank sum or Kruskal—Wallis test was used to compare groups of continuous independent variables. The Kaplan—Meier product-limit method was used to estimate the survival distribution.
The two-sided log-rank test was used to test the association between single categorical variables and survival. Martingale residual plots were used to investigate the association of continuous factors with overall survival. Multivariate analysis was performed using the Cox proportional hazards regression model to determine the associations of two markers with survival after adjusting for the roles of other factors. Statistical analyses were performed using SAS version 8.
The characteristics of the consecutive patients who met the inclusion criteria and were included in the study are shown in Table 1. In all the four disease groups, most patients had a higher blast percentage in BM than in PB.
As a result of the small number of CMML patients with a higher percentage of blasts in PB than in BM, this group was not included in subsequent analyses.
Table 2 shows the correlations of laboratory variables with PB and BM blast percentages, and indicates which levels varied according to the relative blast percentages in PB and BM. In the initial univariate survival analyses we studied most of the known relevant factors, including cytogenetic status, performance status, AHD, age, LDH level, platelet count, B2M level, absolute lymphocyte count, and blast percentage in PB alone and BM alone, as well as the presence of a higher blast percentage in PB than in BM.
Only significant associations are listed in Table 3. Although the percentage of blasts in PB was associated with survival, the percentage of blasts in BM, when considered alone, was not: median overall survival was 9. Survival rates were significantly lower in patients with a higher percentage of blasts in PB than in BM. In patients with ALL, survival was associated with cytogenetic status, performance status, WBC count, absolute lymphocyte count, age, platelet count, and B2M level Table 3.
The presence of a higher percentage of blasts in PB than in BM was not associated with survival, despite the fact that the both the PB and the BM blast percentage, when considered individually, were Table 3 ; Figure 3. Survival rates did not differ significantly between patients with a higher percentage of blasts in PB than in BM and those with a higher percentage of blasts in BM than in PB.
Sixty percent of all ALL cases occur in children, with a peak incidence at age 2 to 5 years; a second peak occurs after age The risk declines slowly until the mids and then begins to rise again slowly after age The average lifetime risk of ALL in both sexes is about 0. Similar to acute myeloid leukemia Acute Myeloid Leukemia AML In acute myeloid leukemia AML , malignant transformation and uncontrolled proliferation of an abnormally differentiated, long-lived myeloid progenitor cell results in high circulating numbers Malignant transformation usually occurs at the pluripotent stem cell level, although it sometimes involves a committed stem cell with more limited capacity for self-renewal.
Abnormal proliferation, clonal expansion, aberrant differentiation, and diminished apoptosis programmed cell death lead to replacement of normal blood elements with malignant cells. In acute lymphoblastic leukemia, the precursor lymphoid neoplasms are broadly categorized based on their lineage into. The major types are Hodgkin lymphoma and non-Hodgkin lymphoma see table Comparison of The World Health Organization WHO classification of lymphoid neoplasms incorporates genetic data, clinical features, cell morphology, and immunophenotype, all of which have important implications for disease prognosis and management.
Symptoms and signs of acute lymphoblastic leukemia may be present for only days to weeks before diagnosis. Anemia can manifest with fatigue, weakness, pallor, malaise, dyspnea on exertion, tachycardia, and exertional chest pain. Hematuria and gastrointestinal bleeding are uncommon. Patients can present with spontaneous hemorrhage, including intracranial or intra-abdominal hematomas.
Granulocytopenia or neutropenia can lead to a high risk of infections, including those of bacterial, fungal, and viral etiologies. Organ infiltration by leukemic cells results in enlargement of the liver, spleen, and lymph nodes. Bone marrow and periosteal infiltration may cause bone and joint pain, especially in children with ALL.
If marrow cells are insufficient or unavailable, diagnosis can be made by the same criteria using a peripheral blood sample. CBC and peripheral smear are the first tests done; pancytopenia and peripheral blasts suggest acute leukemia. Aplastic anemia Aplastic Anemia Aplastic anemia is a disorder of the hematopoietic stem cell that results in a loss of blood cell precursors, hypoplasia or aplasia of bone marrow, and cytopenias in two or more cell lines Fatigue may persist weeks or Deficiency causes megaloblastic anemia, damage It may result from inadequate intake, malabsorption, or use of various drugs.
Deficiency causes megaloblastic anemia indistinguishable from that due to vitamin Unlike in AML, Auer rods linear azurophilic inclusions in the cytoplasm of blast cells are never present in acute lymphoblastic leukemia. Bone marrow examination aspiration and needle biopsy is routinely done. Histochemical studies, cytogenetics, and immunophenotyping studies help distinguish the blasts of ALL from those of AML or other disease processes.
Histochemical studies include staining for terminal deoxynucleotidyl transferase TdT , which is positive in cells of lymphoid origin. Detection of specific immunophenotypical markers such as CD3 for lymphoid cells of T cell origin and CD19, CD20, and CD22 for lymphoid cells of B cell origin is essential in classifying the acute leukemias.
Malignant transformation and uncontrolled proliferation of an abnormally differentiated Causes include chronic kidney disease, hypoparathyroidism, and metabolic or respiratory acidosis. Clinical features There are Patients may also have adverse effects resulting from their cancer. Successfully managing these adverse effects is important Elevated serum hepatic transaminases or creatinine, and hypoglycemia may also be present.
CT of the head is done in patients with CNS symptoms. CT of the chest and abdomen should be done to detect mediastinal masses and lymphadenopathy and may also detect hepatosplenomegaly. Echocardiography or multi-gated acquisition MUGA scanning is typically done to assess baseline cardiac function prior to administration of anthracyclines, which are cardiotoxic. Leukemic cell karyotype t 8;14 , t 8;22 , t 2;8 C-MYC rearranged. Of adults, Poorer adherence to ALL treatment regimens, which include frequent often daily or weekly out-patient chemotherapy and doctor visits.
Most investigatory protocols select patients with poor prognostic factors for more intense therapy because the increased risk of and toxicity from treatment are outweighed by the greater risk of treatment failure leading to death. Sometimes immunotherapy, targeted therapy, stem cell transplantation Hematopoietic Stem Cell Transplantation Hematopoietic stem cell HSC transplantation is a rapidly evolving technique that offers a potential cure for hematologic cancers leukemias, lymphomas, myeloma and other hematologic disorders Treatment for newly diagnosed acute lymphoblastic leukemia generally consists of 3 to 4 cycles of chemotherapy blocks of non—cross-resistant chemotherapy for the first 9 to 12 months, followed by 2.
In patients with complete remission, a low measurable residual disease also known as minimal residual disease or MRD is the most important prognostic factor 1 Treatment references Acute lymphoblastic leukemia ALL is the most common pediatric cancer; it also strikes adults of all ages. Measurable or minimal residual disease is microscopic disease that is not detected by standard assays but can be measured by more sensitive assays.
A low measurable residual disease MRD negativity is defined variably based on the assay used as A high-dose corticosteroid eg, dexamethasone , prednisone. Some regimens use a corticosteroid to reduce disease burden prior to intensive induction. If complete remission is not achieved after induction, some regimens recommend a second induction course to try to get more patients to complete remission before consolidation.
For patients with CD20 positive B-lymphoblastic leukemia, rituximab can be added. The goal of consolidation is to prevent leukemic regrowth. Click here for the steps involved with a new diagnosis of acute leukemia.
Chromosomal changes and genetic mutations are an important prognostic factor for predicting remission rates, relapse risks and survival outcomes. However, not all patients have a chromosomal abnormality, and patients may have different gene mutations from other AML patients.
Your doctor will perform a molecular analysis on your cells to identify specific genetic changes. View the booklet Acute Myeloid Leukemia in Adults for a full listing of chromosome and gene abnormalities. This checklist will help ensure that you receive the best treatment for your unique situation: Click Here. The exact diagnosis helps the doctor to Estimate how the disease will progress Determine the appropriate treatment Diagnosing acute myeloid leukemia AML and your AML subtype usually involves a series of tests.
Blood Tests Blood samples are generally taken from a vein in your arm. Your blood is sent to a lab for the following tests: A complete blood count CBC with differential counts the number of red cells, white cells and platelets in the blood. The CBC should include a differential, which measures the numbers of the different types of white blood cells in the sample. People with AML often have a high number of white blood cells, but most of these are leukemia blast cells that do not protect against infection.
They may also have a low number of red blood cells and platelets. A peripheral blood smear examines the number, shape and size of the red blood cells, white blood cells and platelets to determine whether there are leukemia blast cells in the blood. In patients with AML, many of the white blood cells in the sample may be immature or leukemia blast cells which are not normally found in the circulating blood.
Bone Marrow Tests Samples of marrow cells are obtained by bone marrow aspiration and biopsy.
0コメント